Accessibility Menu
Veraxa Biotech Ag logo

Veraxa Biotech Ag(NASDAQ) VRXA

Market Cap$56.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-82%
5 YearN/A
1 Year-83%
1 Month-22%
$2.08
+15.56%
+0.28Today
Veraxa Biotech Ag last closing stock price
MetricPriceDate
Last closeUSD 1.802026-07-24
Veraxa Biotech Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-17.43%USD 2.182026-07-17
1 month-21.74%USD 2.302026-06-24
3 month-86.15%USD 13.002026-04-24
Year to date-83.13%USD 10.672025-12-31
1 year-82.68%USD 10.392025-07-24
Since inception-81.95%USD 9.972024-09-30

Veraxa Biotech Ag Financials at a Glance

Market Cap

$56.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$6.74

EPS (TTM)

$0.21

P/E Ratio

8.40

Dividend

$0.00

Beta (Volatility)

0.57 (Low)

Price

$2.08

Volume

28,554

Open

$1.91

Previous Close

$2.08

Daily Range

$1.90 - $2.24

52-Week Range

$1.70 - $27.36

Estimated Earnings Date

N/A

VRXA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Veraxa Biotech Ag

Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, including antibody-drug conjugates (ADCs) and bispecific T-cell engagers. Formed through a merger with Voyager Acquisition Corp., the company aims to address unmet medical needs in oncology.

Products and Services
  • Development of next-generation cancer therapies
  • Focus on antibody-drug conjugates (ADCs)
  • Innovative bispecific T-cell engagers for targeted treatment
Growth Outlook
  • Strong market potential in the oncology sector
  • Increasing demand for advanced cancer therapies
  • Strategic partnerships to enhance research and development
Financial Highlights
  • Market capitalization of approximately $295 million
  • Stock price range between $1.70 and $27.36 over the past year
  • Low beta of 0.25 indicates lower volatility compared to the market
Veraxa Biotech Holding AG operates in the dynamic biotechnology industry, focusing on innovative solutions for cancer treatment. The company's commitment to developing advanced therapies positions it well within a growing market. With a market capitalization of around $295 million, Veraxa is strategically placed to leverage partnerships and research opportunities. The stock has experienced a significant price range over the past year, reflecting investor interest and market potential. The low beta indicates that the stock is less volatile than the overall market, which may appeal to risk-averse investors. Overall, Veraxa Biotech Holding AG represents a compelling opportunity in the biopharmaceutical sector.
AI Generated • Jul 14, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3

CEO

Christoph Antz, PhD

Website

www.voyageracq.com

Headquarters

Heidelberg, ZH 69120, DE

VRXA Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

5.72%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

11.90%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$56.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

31.63M

Volume

28.55K

Avg. Volume

414.20K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Veraxa Biotech Ag Performance Analysis

Veraxa Biotech Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Veraxa Biotech Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -0.00N/A
20242024-12-31USD 0.13N/A
20252025-12-31USD 0.28116.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

N/A

N/A

Market Cap

$56.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$126.61

N/A

Employees

3

N/A

Net Income

$0.18

+0.1%

EBITDA

-$2.19

+8.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$0.03

-92.6%

Total Debt

$0.00

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

2.52%

+0.5%

Return on Invested Capital

35.06%

N/A

Free Cash Flow

-$0.15

+0.7%

Operating Cash Flow

-$0.15

+0.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,396.49-0.00%
^DJIDJI
$52,083.00+0.00%
^IXICNASDAQ
$24,847.16-0.01%
BTCBitcoin
$64,796.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%

Questions About VRXA

What is the current price of Veraxa Biotech Ag?

Veraxa Biotech Ag is trading at $2.08 per share.

What is the 52-week range for Veraxa Biotech Ag?

Over the past 52 weeks, Veraxa Biotech Ag has traded between $1.70 and $27.36.

How much debt does Veraxa Biotech Ag have?

As of the most recent reporting period, Veraxa Biotech Ag reported total debt of $0.00.

How much cash does Veraxa Biotech Ag have on hand?

Veraxa Biotech Ag reported $32.79K in cash and cash equivalents in its most recent financial results.

What is Veraxa Biotech Ag’s dividend yield?

Veraxa Biotech Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services